Recurrent headache was reported by 61% of patients with thalassemia compared with 22.5% of healthy individuals in a control arm.
Allogeneic HSC gene therapy may be an alternative to transplantation for patients with transfusion-dependent thalassemia.
A high percentage of patients with beta thalassemia demonstrated an increase in hemoglobin levels after receiving luspatercept.
A new oral iron chelator, deferasirox, may confer long-term benefits to patients with beta thalassemia major.
Modern tools for measuring health-related quality of life may not capture symptoms unique to patients with nontransfusion-dependent thalassemia.
Accessing peripheral blood as a graft source is easier and less invasive than accessing bone marrow.
Iron overload that persists after HSCT can cause long-term organ damage.
Mortality in beta-thalassemia has decreased due to medical advances, allowing physicians to observe and manage disease-related complications in adult patients.